BLAINHALATIONPOWDER
Approved
Jun 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
AFREZZA (insulin human) by Eli Lilly and Company is fat, and by inhibiting hepatic glucose production. First approved in 2014.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AFREZZA is an inhaled human insulin powder approved by the FDA in 2014 for rapid-acting mealtime insulin delivery in patients with diabetes. It works via the standard insulin mechanism: promoting glucose uptake in muscle and fat, inhibiting hepatic glucose production, and suppressing lipolysis and proteolysis. This novel inhalation route differentiates it from traditional injectable insulins.
$0.023BPart D
PeakAFREZZA is in peak lifecycle stage with modest Part D spending of $23M (2023), indicating a niche market position that likely supports a specialized, focused commercial team rather than large-scale field operations.
Mechanism of Action
fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Pharmacologic Class:
Insulin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections
Started Feb 2019
29 enrolled
Type 2 Diabetes Treated With Insulin
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Started Jan 2011
13 enrolled
DiabetesDiabetes Mellitus, Type 1
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Started Aug 2008
28 enrolled
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Started Jul 2008
42 enrolled
Diabetes
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
Started Jan 2008
25 enrolled
Diabetes Mellitus
Worked on AFREZZA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.